All Resources
Our resource hub to discover reports, policy papers and other forms of informative content
Cost Drivers Report 2023
Annual cost growth in Canada’s private drug benefit market is driven by increased utilization and chronic disease drugs, with an increase in claimants post‑pandemic. Read the full report….
Two years is too long – Understanding Canada’s Drug Access Pathway
Canadians wait two years for access to new medicines through our public drug plans. That’s a full year longer than patients in most other peer countries. Two years can feel…
Cost of A Private Drug Plan Claim
IMC contracted Reformulary Group to analyze the cost of a private plan prescription drug claim in Canada, and separately in Quebec. This report summarizes that analysis….
Developing a Canadian managed entry approach for new innovation: What can Canada learn from Europe?
Many new therapies coming to the market are not well served by the traditional drug reimbursement approaches currently employed by Canada’s public plans. A growing number of European regulatory authorities…